切换至 "中华医学电子期刊资源库"
高级检索
中华普外科手术学杂志(电子版)

中华普外科手术学杂志(电子版) ›› 2021, Vol. 15 ›› Issue (04) : 430 -433. doi: 10.3877/cma.j.issn.1674-3946.2021.04.021

论著

可扩张支架置入联合新辅助化疗后行择期左半结肠根治术治疗梗阻性左半结肠癌
程思俊1, 杨驭媒2, 袁波1, 卢建利3, 邓超4,†()   
  1. 1. 610051　成都，成都市第六人民医院沙河院区胃肠外科
    2. 610051　成都，成都市第六人民医院沙河院区检验科
    3. 610041　成都，三六三医院肝胆胰外科
    4. 643000　四川自贡，自贡市第一人民医院普外科
  • 收稿日期:2020-08-04 出版日期:2021-08-17
  • 通信作者: 邓超

Selective left hemicolectomy after expandable stent placement to relieve obstruction combined with neoadjuvant chemotherapy in the treatment of obstructive left colon cancer

Sijun Cheng1, Yumei Yang2, Bo Yuan1, Jianli Lu3, Chao Deng4,†()   

  1. 1. Gastrointestinal Surgery, Shahe Hospital, Chengdu Sixth People’s Hospital Chengdu, sichuan 610051, China
    2. Clinical Laboratory of Chengdu Sixth People’s Hospital Chengdu, sichuan 610051, China
    3. Department of Hepatobiliary and pancreatic Surgery, 363 Hospital Chengdu, sichuan 610041, China
    4. General Surgery Department, Zigong First People’s Hospital Sichuan zigong 643000, China
  • Received:2020-08-04 Published:2021-08-17
  • Corresponding author: Chao Deng
  • Supported by:
    Scientific Research Project of Sichuan Health Commission-Key Research Projects(19ZD032); Application Foundation Project of Sichuan Science and Technology Department(2019YJ0133)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

程思俊, 杨驭媒, 袁波, 卢建利, 邓超. 可扩张支架置入联合新辅助化疗后行择期左半结肠根治术治疗梗阻性左半结肠癌[J/OL]. 中华普外科手术学杂志(电子版), 2021, 15(04): 430-433.

Sijun Cheng, Yumei Yang, Bo Yuan, Jianli Lu, Chao Deng. Selective left hemicolectomy after expandable stent placement to relieve obstruction combined with neoadjuvant chemotherapy in the treatment of obstructive left colon cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(04): 430-433.

目的

研究梗阻性左半结肠癌患者可扩张支架置入解除梗阻联合新辅助化疗(NC)后择期行左半结肠根治术的临床疗效。

方法

选取2018年1月至2019年3月两家医院治疗的梗阻性左半结肠癌患者70例，根据治疗方法不同分为两组，各35例。联合组患者在数字减影造影(DSA)引导下可扩张支架置入解除梗阻同期联合NC治疗后择期行左半结肠根治术，对照组患者不做NC治疗，其余治疗相同。采用软件SPSS23.0进行统计学分析。围术期指标等计量资料采用(±s)表示，行独立t检验；并发症等计数资料采用χ2检验，P<0.05表示差异有统计学意义。

结果

两组患者支架置入并发症总发生率比较差异无统计学意义(14.3% vs. 20.0%, P＝0.526)，联合组患者新辅助化疗毒副反应轻，符合手术指征。联合组患者手术时间、术中出血量、术中造口数量、术后引流量、首次排便/进食时间、术后住院时间及术后并发症均显著优于对照组，组间差异有统计学意义(P<0.05)。

结论

DSA引导下可扩张支架置入术联合NC后择期行左半结肠根治术治疗梗阻性左半结肠癌，具有缩短手术时间、降低造口率和并发症发生率，有利于患者术后康复。

关键词: 结肠肿瘤, 支架, 新辅助化疗, 血管造影术, 数字减影
Objective

To study the clinical effect of selective radical resection of left colon in patients with obstructive left colon cancer after the removal of obstruction by dilatable stent implantation combined with neoadjuvant chemotherapy (NC).

Methods

A total of 70 patients with obstructive left colon cancer treated in two hospitals from January 2018 to March 2019 were selected. According to different treatment methods, the patients were divided into two groups with 50 cases each. Under the guidance of digital subtraction angiography (DSA), patients in the combined group were treated with dilated stent to relieve obstruction. After the concurrent NC treatment, the left semicolon was selected for radical resection. Patients in the control group did not receive NC treatment, and other treatments were the same.SPSS23.0 software was used for statistical analysis. Measurement data such as perioperative indicators were represented by (±s), and independent t test was performed.The data of complications were tested by χ2 test, and P<0.05 indicated a statistically significant difference.

Results

There was no statistically significant difference in the total incidence of stent implantation complications between the two groups (14.3% vs. 20.0%, P=0.526), and the toxic and side effects of neoadjuvant chemotherapy were mild in the combined group, consistent with the indications of surgery. The operative time, intraoperative blood loss, intraoperative stoma number, postoperative drainage volume, time of first defecation/feeding, postoperative hospital stay and postoperative complications of the combined group were significantly better than those of the control group, and the differences between the two groups were statistically significant (P<0.05).

Conclusion

Under the guidance of DSA, expansive stent implantation combined with neoadjuvant chemotherapy can be performed at an optional time for the treatment of obstructed left colon cancer, which can shorten the operation time, reduce the rate of stoma and complications, and is conducive to the postoperative rehabilitation of patients.

Key words: Colonic neoplasms, Stents, Neoadjuvant chemotherapy, Angiography, digital subtraction
表1 70例梗阻性左半结肠癌患者不同治疗方法两组一般资料比较[(±s)，例]
组别 例 肿瘤直径 BMI (kg/m2) 年龄(岁) 性别 肿瘤位置 TNM分期 肠梗阻类型 ECOG评分 KPS评分
男/女 A/B/C/D T3N0/ T3N1/T3N2 E/F/G
联合组 35 5.9±1.3 22.3±3.1 50.3±7.6 22/13 10/3/18/4 24/10/1 25/7/3 0.5±0.2 86.2±3.1
对照组 35 6.0±1.4 22.8±3.5 51.5±7.1 18/17 13/2/15/5 23/11/1 23/8/4 0.4±0.5 85.7±2.9
t/χ2值   0.390 0.478 1.152 0.933 7.611 0.069 0.293 1.099 0.697
P值   0.379 0.582 0.126 0.333 0.807 0.966 0.864 0.137 0.244
表2 70例梗阻性左半结肠癌患者不同治疗方法两组术前并发症情况比较(例)
组别 例 间断便血 腹痛 大量便血 肠穿孔 支架移位 严重肠管水肿 总发生率(%)
联合组 35 1 2 1 0 0 1 5(14.3)
对照组 35 1 2 1 1 1 1 7(20.0)
χ2值               0.402
P值               0.526
表3 70例梗阻性左半结肠癌患者不同治疗方法两组围术指标比较(±s)
组别 例 手术时间(min) 术中出血量(ml) 术中造口(例) 术后引流量(ml)
联合组 35 121.5±33.8 100.2±91.2 1 276.1±35.8
对照组 35 162.4±36.9 199.0±109.4 9 290.6±33.2
t/χ2值   3.471 5.327 7.611 1.757
P值   <0.001 <0.001 <0.01 <0.05
组别 例 首次排便时间(d) 进食时间(d) 术后住院时间(d)
联合组 35 3.1±2.1 1.2±0.8 13.4±3.4
对照组 35 5.7±3.8 1.7±1.1 21.5±4.1
t/χ2值   0.038 2.175 0.093
P值   <0.01 <0.05 <0.05
表4 70例梗阻性左半结肠癌患根治术后两组术后并发症水平比较(例)
组别 例 肺部感染 腹腔感染 伤口感染 吻合口漏 肠内出血 肠壁水肿 总发生率(%)
联合组 35 1 0 1 0 0 0 2(5.7)
对照组 35 2 2 2 1 1 2 10(28.7)
χ2值               6.437
P值               <0.05
[1]
吴康，崔刚．左半结肠切除一期吻合加回肠末端造瘘治疗老年梗阻性左半结肠癌的临床效果[J/CD]．中华普外科手术学杂志(电子版)，2019，13(1)：99-101.
[2]
Ormando VM, Palma R, Fugazza A, et al. Colonic stents for malignant bowel obstruction: current status and future prospects[J]. Expert Rev Med Devices, 2019, 16(4): 1-9.
[3]
韩加刚，王振军．梗阻性左半结肠癌治疗新策略-支架扩张联合新辅助化疗[J]．临床外科杂志，2020，28(5)：401-403.
[4]
崔君鹏，林美艺，吴华锦，等．支架植入时间对左半结肠癌伴急性梗阻患者术后生存率的影响[J]．中国医科大学学报，2020，49(2)：175-178.
[5]
Hatano S, Sakamoto S, Yamamoto E, et al. Does Colonic Stenting Affect the Long-Term Prognosis of Colorectal Cancer？[J]. Gan To Kagaku Ryoho, 2020, 47(3): 478-480.
[6]
中华人民共和国卫生和计划生育委员会医政医管局，中华医学会肿瘤学分会．中国结直肠癌诊疗规范(2017年版) [J]. 中华外科杂志，2018，56(4) ：241-258.
[7]
Han JG, Wang ZJ, Dai Y, et al. Preliminary report on prospective, multicenter, open research of selective surgery after expandable stent combined with neoadjuvant chemotherapy in the treatment of obstructive left hemicolon cancer[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2018, 21(11): 1233-1239.
[8]
艾超，冀召帅，唐蕾，等. 抗肿瘤药物毒性分级及防护标准的建立与实施[J]. 医药导报，2019，38(9)：1238-1240.
[9]
Boland PA, Kelly ME, Donlon NE, et al. Outcomes following colonic stenting for malignant left-sided bowel obstruction: a systematic review of randomised controlled trials[J]. Int J Colorectal Dis, 2019, 34(10): 1625-1632.
[10]
Maruo H, Iwase Y, Sekimoto A, et al. Short-Term and Long-Term Outcomes of Colonic Stenting as a Bridge to Surgery for Obstructive Colorectal Cancer[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2002-2004.
[11]
Wang YC. Effect of preoperative neoadjuvant chemotherapy on the expression of malignant molecules in colon cancer tissue and the degree of trauma caused by radical operation Yan-Cheng Wang[J]. Journal of Hainan Medical University, 2017, 23(17): 113-116.
[12]
Pisano M, Zorcolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation [J]. World J Emerg Surg, 2018, 13(36): 2-27.
[13]
Velazquez E, Brindley TD, Shrestha G, et al. Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells[J]. Cancer Cell Int, 2020, 20(1): 127.
[14]
Kasi PM, Kamatham S, Shahjehan F, et al. BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer[J]. J Gastrointest Oncol, 2020, 11(2): 236-241.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 571-579.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[4] 康婵娟, 张海涛, 翟静洁. 胰管支架置入术治疗急性胆源性胰腺炎的效果及对患者肝功能、炎症因子水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 667-670.
[5] 崔宏帅, 冯丽明, 东维玲, 韩博. 腹腔镜右半结肠癌D3根治术+IGLN清扫术治疗局部进展期结肠肝曲癌的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 566-569.
[6] 丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[7] 王维花, 王楠, 乔庆, 罗红. 完全腹腔镜右半结肠癌切除术两种腔内消化道重建方案对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 574-577.
[8] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[9] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[10] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[11] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 关国欣, 罗福文. 结肠癌合并急性梗阻的个性化处理[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 459-463.
[14] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[15] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号